Pui San Loh

Dr. Pui San Loh

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 June 2017 in BMC Anesthesiology
Verified
Journal Article
Open access
PDF file
VRVineya Rai Hakumat Rai
Vineya Rai Hakumat Rai
LPLee Fern Phang
Lee Fern Phang
SSSheau Fung Sia
Sheau Fung Sia
AAAmirah Amir
Amirah Amir
JVJeyaganesh S. Veerakumaran
Jeyaganesh S. Veerakumaran
GOGracie Ong
Gracie Ong
Head injury is one of the top three diagnosis leading to intensive care unit (ICU) admission in Malaysia. There has been growing interest in using immunonutrition as a mode of modulating the inflammatory response to injury or infection with the aim of improving clinical outcome. The aim of the present study was to evaluate the effect of an immunonutrition on biomarkers (IL-6, glutathione, CRP, total protein and albumin) in traumatic brain injury patients. Thirty six patients with head injury admitted to neurosurgical ICU in University Malaya Medical Centre were recruited for this study, over a 6-month period from July 2014 to January 2015. Patients were randomized to receive either an immunonutrition (Group A) or a standard (Group B) enteral feed. Levels of biomarkers were measured at day 1, 5 and 7 of enteral feeding. Patients in Group A showed significant reduction of IL-6 at day 5 (p < 0.001) with concurrent rise in glutathione levels (p = 0.049). Patients in Group A also demonstrated a significant increase of total protein level at the end of the study (day 7). These findings indicate the potential of immunonutrition reducing cytokines and increasing antioxidant indices in patients with TBI. However, further studies incorporating patient outcomes are needed to determine its overall clinical benefits. National Medical Research Register (NMRR) ID: 14–1430-23,171. ClinicalTrials.gov identifier: NCT03166449 .

1 December 2018 in Prostaglandins, Leukotrienes and Essential Fatty Acids
Verified
Journal Article
Closed access
ABAnne Barden
Anne Barden
MPMichael Phillips
Michael Phillips
LHLisa M. Hill
Lisa M. Hill
EFEvelyn M. Fletcher
Evelyn M. Fletcher
EMEmilie Mas
Emilie Mas
TCTomás B. Corcoran
Tomás B. Corcoran

4 May 2024 in Clinical Pharmacokinetics
Verified
Journal Article
Closed access
PDF file
KFKeng Wah Foong
Keng Wah Foong
SCSook Hui Chaw
Sook Hui Chaw
YLYokeLin LO
YokeLin LO
PLPui San Loh
Pui San Loh

1 August 2020 in Prostaglandins & Other Lipid Mediators
Verified
Journal Article
Closed access
ABAnne Barden
Anne Barden
MPMichael Phillips
Michael Phillips
EMEmilie Mas
Emilie Mas
LHLisa M. Hill
Lisa M. Hill
IMIan Mowat
Ian Mowat
Trevor MoriTrevor Mori
Trevor Mori

11 October 2017 in BMC Anesthesiology
Verified
Journal Article
Open access
PDF file
PLPui San Loh
Pui San Loh
MMM.M. Miskan
M.M. Miskan
CYChin Y.Z.
Chin Y.Z.
RZRafdzah Ahmad Zaki
Rafdzah Ahmad Zaki
Cough on emergence has been reported as a common adverse reaction with sugammadex reversal. We investigated if staggering the dose of sugammadex will reduce emergence cough in a single-center, randomized, double-blinded study. A hundred and twenty ASA 1–3 adults were randomly reversed with 1 mg/kg sugammadex prior to extubation followed by another 1 mg/kg immediately after extubation (staggered group), single dose of 2 mg/kg sugammadex (single bolus group) or neostigmine 0.02 mg/kg with glycopyrrolate (neostigmine group). We found 70% of patients (n = 28) reversed with single boluses of sugammadex had Grade 3 emergence cough compared to 12.5% (n = 5) in the staggered sugammadex group and 17.5% (n = 7) in the neostigmine group (p < 0.001). Besides cough, emergence agitation also appeared highest in the single bolus sugammadex group (n = 14, 35%, p = 0.005). On the other hand, staggering sugammadex lowered risks of developing severe cough (RR 0.2, p < 0.001) and agitation (RR 0.43, p = 0.010) on emergence in addition to cough (RR 0.25, p = 0.039) and early sore throat (RR 0.70, p = 0.036) in the post-anesthetic care unit. The risks for severe emergence cough (RR 0.86, p = 0.762), severe cough in the post-anesthetic care unit (RR 1.0, p = 1.000) and sore throat (RR 1.17, p = 0.502) were also not different between the staggered sugammadex group and control given neostigmine. In terms of timing, there was no delay in time taken from discontinuing anesthetic agents to reversal and extubation if sugammadex was staggered (emergence time 6.0 ± 3.2 s, p = 0.625 and reversal time 6.5 ± 3.5, p = 0.809). Staggering the dose of sugammadex for reversal will effectively decrease common emergence and early postoperative complications. ANZCTR Number ACTRN12616000116426 . Retrospectively registered on 2nd February 2016.

1 January 2022 in Asian Journal of Surgery
Verified
Journal Article
Open access
RRRuveena B. Rajaram
Ruveena B. Rajaram
TJThevaraajan Jayaraman
Thevaraajan Jayaraman
BYBoon-Koon Yoong
Boon-Koon Yoong
PKPeng-Soon Koh
Peng-Soon Koh
PLPui San Loh
Pui San Loh
SMSanjiv Mahadeva
Sanjiv Mahadeva
Obesity and non-alcoholic fatty liver disease (NAFLD) are rampant in South East Asia. There is paucity of data exploring its' impact on donor suitability for living donor liver transplantation (LDLT). We aimed to describe and examine the factors related to non-utilization of potential donors in our LDLT programme. This is an analysis of prospectively collected data on potential donors for an adult LDLT programme, between January 2017 and December 2019. Fifty-five donors for 33 potential recipients were evaluated. The mean age was 31.6 ± 8.5 years, 52.7% were female and the ethnic divisions were: Chinese (50.9%), Indian (25.5%) and Malay (23.6%). The mean body mass index (BMI) among potential donors was 25.1 ± 4.0 kg/m2; 25.5% of donors had normal BMI, 23.6% were overweight and 50.9% were obese. Using the CAP modality of Fibroscan®, we identified the following grades of hepatic steatosis: 36.6% S0, 19.5% S1, 2.4% S2 and 41.5% S3. The non-utilization rate of our donors was 74.5% (41/55) and the main reasons were significant hepatic steatosis and/or obesity. Compared to suitable donors, unsuitable donors had significantly greater mean BMI, mean CAP scores, higher rates of dyslipidaemia and NAFLD. NAFLD and obesity represent major challenges to an emerging LDLT programme in Malaysia.